November 5, 2024: MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes
MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes [fancy-ul icon_type="standard_dash" color="Accent-Color" alignment="left" spacing="default"] Completion of enrollment in the European Phase 3 clinical trial ARES designed to evaluate efficacy and safety of MaaT013 in the treatment of acute Graft-versus-Host Disease; topline results expected in January 2025. Positive safety assessment by [...] 
